Art Original
Conjugation of methotrexate to gelatin and its characterization
methotrexate (MTX) and gelatin have been explored as an anticancer agent an a drug matrix, respectively. previous studies have shown that conjugation of mtx to macromolecules generally produced a greater effect on inhibition of tumor growth than does free mtx. when gelatin was conjugated with an anticancer agent, it showed a greater effect on inhibition of tumor growth than does the anticancer agent as well. one study reported using methotrexate as the drug and gelatin as the carrier to make an mtx-gelatin conjugate at ph4.7. sience little information could be extracted from this report, further studies were planned. hypotheses were proposed that: (i) mtx-gelatin conjugates can be made using 1-ethly-3-(3-diaminopropyl) carbodiimide hydrochloride (edc) as the coupling agent, and the reactions will be affected by ph, amounts of edc, and amounts of mtx; (ii) release kinetics of mtx from the conjugates will follow a first-order mechanism at 25, 37, and 50 derjat celcius for 72 hours at ph 7.4; (iii) the release rate increases with increasing temperature and (iv) there will be no differences between mtx release rates from low and high molecular weight conjugates of gelatin. mtx and gelatin contents in the conjugates were measured spectrophotometrically and water content was determined thermogravimetrically. mtx release from the conjugates was studied using adialysis cassette. mtx concentration was determined by reverse phase hplc. conjugate fragments of low molecular weight containing mtx were also released. generally, results supported the hypotheses. there was no statistically significant difference between the release rate of mtxfrom the conjugates made of gelatin of low molecular weight and that of high molecular weight. the calculated activattion energies of mtxlinked to gelatin was (15.2+3.4_kcal/mole.
Tidak tersedia versi lain